Moreover, certain sources suggest that the TAM/CXCL1/NF-κB/FOXP3 signaling pathway could potentially serve as a therapeutic target to modulate Tregs and enhance immunotherapy for BC [25]. This evidence concerns the gene NFKB1 and breast cancer.